MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Viridian Therapeutics, Inc. DE (VRDN)

Viridian Therapeutics, Inc. DE (VRDN)

|||

Balance Sheets Overview

Current Ratio
1694.94%
Quick Ratio
1694.94%
Debt to Asset Ratio
39.66%
Unit: Thousand (K) dollars
Assets Breakdown
    • Marketable securities
    • Cash and cash equivalents
    • Other receivable
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Liability related to the sale of...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Cash and cash equivalents
164,986
176,346
169,647
117,324
Marketable securities
816,544
585,835
321,254
446,032
Unbilled revenue
-
-
70,000
-
Other receivable
75,000
-
-
-
Prepaid expenses and other current assets
24,740
22,563
11,012
15,394
Total current assets
1,081,270
784,744
571,913
578,750
Property and equipment, net
2,765
1,130
1,125
1,091
Operating lease right-of-use asset
2,085
2,255
2,582
1,977
Intangible asset, net
10,000
-
-
-
Other assets
1,113
888
1,518
506
Total assets
1,097,233
789,017
577,138
582,324
Current portion of long-term debt
-
-
-
8,435
Current portion of deferred revenue - related party
-
-
-
288
Accounts payable
8,652
13,313
10,063
8,518
Long-term debt
-
-
20,890
12,353
Accrued liabilities
55,142
38,492
40,633
35,344
Total current liabilities
63,794
51,805
50,696
52,585
Long-term debt, net
0
50,436
-
-
Derivative liability
13,690
12,500
-
-
Liability related to the sale of future revenue, net
113,642
36,092
-
-
Convertible notes, net
242,159
-
-
-
Other liabilities
1,851
2,176
2,582
2,077
Deferred revenue - related party
-
-
-
140
Total liabilities
435,136
153,009
74,168
67,155
Preferred stock-Series APreferred Stock
60,432
61,188
61,188
61,188
Preferred stock-Series BPreferred Stock
37,592
70,868
127,697
127,697
Common stock, 0.01 par value 200,000,000 shares authorized 113,238,218 and 101,826,500 shares issued and outstanding as of june30, 2026 and december31, 2025, respectively
1,132
1,025
822
817
Additional paid-in capital
2,134,572
1,946,844
1,531,003
1,508,902
Accumulated other comprehensive income (loss)
-1,153
-558
363
69
Accumulated deficit
-1,570,478
-1,443,359
-1,218,103
-1,183,504
Total stockholders equity
662,097
636,008
502,970
515,169
Total liabilities and stockholders equity
1,097,233
789,017
577,138
582,324
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities$816,544K (83.07%↑ Y/Y)Cash and cashequivalents$164,986K (40.62%↑ Y/Y)Other receivable$75,000K Prepaid expenses andother current assets$24,740K (60.71%↑ Y/Y)Total current assets$1,081,270K (86.83%↑ Y/Y)Intangible asset, net$10,000K Property and equipment,net$2,765K (153.44%↑ Y/Y)Operating leaseright-of-use asset$2,085K (5.46%↑ Y/Y)Other assets$1,113K (119.96%↑ Y/Y)Total assets$1,097,233K (88.42%↑ Y/Y)Total liabilities andstockholders equity$1,097,233K (88.42%↑ Y/Y)Total stockholdersequity$662,097K (28.52%↑ Y/Y)Total liabilities$435,136K (547.96%↑ Y/Y)Accumulated deficit-$1,570,478K (-32.70%↓ Y/Y)Accumulated othercomprehensive income (loss)-$1,153K (-1771.01%↓ Y/Y)Additional paid-in capital$2,134,572K (41.47%↑ Y/Y)Convertible notes, net$242,159K Liability related to thesale of future...$113,642K Total currentliabilities$63,794K (21.32%↑ Y/Y)Derivative liability$13,690K Other liabilities$1,851K (-10.88%↓ Y/Y)Preferred stock-SeriesAPreferred Stock$60,432K (-1.24%↓ Y/Y)Preferred stock-SeriesBPreferred Stock$37,592K (-70.56%↓ Y/Y)Common stock, 0.01 parvalue 200,000,000...$1,132K (38.56%↑ Y/Y)Accrued liabilities$55,142K (56.02%↑ Y/Y)Accounts payable$8,652K (1.57%↑ Y/Y)